Fig. 1: Targeting NAT10 sensitizes HCC cells and mouse xenografts to chemotherapy.

A IHC staining of NAT10 in HCC and normal liver tissues from the HPA database. Average optical density data were analyzed by one-way ANOVA and presented as mean ± SEM **P < 0.01. B Kaplan–Meier survival analysis of the overall survival probability of patients with HCC according to NAT10 expression (high, n = 79; low, n = 286). C Western blot (WB) analysis of NAT10 expression in OXA-resistant Huh7 cells and parental Huh7 cells. D The schematic diagram of NAT10’s shRNAs (upper panel). WB was performed on the cell lysates to evaluate NAT10 levels in Huh7-NAT10 shRNA-1, Huh7-NAT10 shRNA-2, and Huh7-control shRNA cells (lower panel). E The IC50 of doxorubicin and oxaliplatin in Huh7-NAT10 shRNA-1, Huh7-NAT10 shRNA-2, and Huh7-control shRNA cells. Data were analyzed by one-way ANOVA and presented as mean ± SD (n = 3). F Huh7 cells were transfected with Flag-vector, Flag-NAT10 or Flag-NAT10 G641E plasmids. WB was performed on the cell lysates to evaluate Flag-NAT10 and Flag-NAT10 G641E levels. G The IC50 of doxorubicin and oxaliplatin in Huh7 cells expressing Flag, Flag-NAT10 or Flag-NAT10 G641E. Data were analyzed by one-way ANOVA and presented as mean ± SD (n = 3). H Huh7-NAT10 shRNA-1, Huh7-NAT10 shRNA-2, and Huh7-control shRNA cells were subcutaneously implanted into nude mice. Oxaliplatin (5 mg/kg) was intraperitoneally injected twice a week after Huh7 cells injection (n = 6). I The volumes of tumor xenografts were shown. Data were analyzed by one-way ANOVA and presented as mean ± SD, ***P < 0.001. J Tumors were dissected at the end of the experiment. K Tumor tissues were stained with HE. Scale bar, 50 μm. L The weights of tumor xenografts were shown. Data were analyzed by one-way ANOVA and presented as mean ± SD, ***P < 0.001.